Enzyme replacement therapy and fatigue in adults with Pompe disease (Q45382449)

14 December 2017

title

Enzyme replacement therapy and fatigue in adults with Pompe disease (English)

1 reference

enzyme replacement therapy

14 December 2017

main subject

0 references

9

Pieter A van Doorn

1 reference

14 December 2017

3

Esther Brusse

1 reference

14 December 2017

12

Ans T van der Ploeg

1 reference

14 December 2017

8

Arnold J J Reuser

1 reference

14 December 2017

10

Marloes L C Hagemans

1 reference

14 December 2017

Michelle E Kruijshaar

4

object named as

Michelle E Kruijshaar

1 reference

14 December 2017

2

Juna M de Vries

1 reference

14 December 2017

1

Deniz Güngör

1 reference

14 December 2017

Wim C J Hop

5

1 reference

14 December 2017

Magda Murawska

6

1 reference

14 December 2017

Linda E M van den Berg

7

1 reference

14 December 2017

Iris Plug

11

1 reference

14 December 2017

language of work or name

1 reference

3 April 2013

1 reference

Molecular Genetics and Metabolism

14 December 2017

published in

1 reference

14 December 2017

volume

109

1 reference

14 December 2017

issue

2

1 reference

14 December 2017

page(s)

174-178

1 reference

Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Fatigue in neurological disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Fatigue: an important feature of late-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Respiratory failure in Pompe disease: treatment with noninvasive ventilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

A randomized study of alglucosidase alfa in late-onset Pompe's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

The assessment of fatigue: a practical guide for clinicians and researchers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

The hospital anxiety and depression scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

The validity of the Hospital Anxiety and Depression Scale. An updated literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Fat and carbohydrate metabolism during exercise in late-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

An examination of four models predicting fatigue in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Temporal relations between unexplained fatigue and depression: longitudinal data from an international study in primary care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Depression in multiple sclerosis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2013.03.016

10.1016/J.YMGME.2013.03.016

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference